About the Vaccine

MMR and MMRV Vaccine Composition and Dosage

Two vaccines containing measles, mumps, and rubella virus are licensed for use in the United States.

• M-M-R II® is a combination measles, mumps, and rubella (MMR) vaccine.
• ProQuad® is a combination measles, mumps, rubella, and varicella (MMRV) vaccine.

Both vaccines contain live, attenuated measles, mumps, and rubella virus. MMRV also contains live, attenuated varicella-zoster virus. All vaccine strains, including the Moraten strain (used in the United States) and the Edmonston- Zagreb strain are in genotype A.

The lyophilized live MMR vaccine and MMRV vaccine should be reconstituted and administered as recommended by the manufacturer^1,2.

For package inserts, see M-M-R II, ProQuad

Footnotes

 Top of Page

MMR Vaccine Effectiveness and Duration of Protection

Vaccine Effectiveness

One dose

• 1 dose of MMR vaccine is—
  • 93% effective for measles (range: 39%–100%)
  • 78% effective for mumps (range: 49%−92%)
  • 97% effective for rubella (range: 94%–100%)

Two doses

• 2 doses of MMR are—
  • 97% effective for measles (range: 67%–100%)
  • 88% effective for mumps (range: 66%-95%)

Duration of Protection

People who receive MMR vaccination according to the U.S. vaccination schedule are considered protected for life.

• Both serologic and epidemiologic evidence indicate that vaccine-induced measles immunity appears to be long-term and probably lifelong in most persons.
• Studies indicate that one dose of vaccine confers long-term, probably lifelong, protection against rubella.
• Studies indicate that 1 dose of MMR vaccine can provide persistent antibodies to mumps.

 Top of Page

Vaccine Safety

The United States' long-standing vaccine safety program closely and constantly monitors the safety of vaccines. See in-depth information about the safety of each FDA-approved vaccine:

• Measles, Mumps, and Rubella (MMR) Vaccine
• Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine